Olstein Capital Management L.P. Sells 7,000 Shares of Hologic, Inc. (NASDAQ:HOLX)

Olstein Capital Management L.P. cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 7.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 85,000 shares of the medical equipment provider’s stock after selling 7,000 shares during the quarter. Olstein Capital Management L.P.’s holdings in Hologic were worth $6,924,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Wolff Wiese Magana LLC bought a new stake in shares of Hologic during the third quarter worth $25,000. Innealta Capital LLC acquired a new stake in shares of Hologic during the 2nd quarter valued at $25,000. iA Global Asset Management Inc. acquired a new stake in shares of Hologic during the 1st quarter valued at $37,000. Sunbelt Securities Inc. bought a new stake in Hologic during the 2nd quarter worth $37,000. Finally, Cromwell Holdings LLC increased its holdings in Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 416 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Down 0.9 %

Shares of NASDAQ HOLX traded down $0.69 during trading on Thursday, hitting $79.80. The stock had a trading volume of 51,248 shares, compared to its average volume of 1,588,134. The firm has a fifty day moving average of $81.05 and a two-hundred day moving average of $78.12. The company has a market capitalization of $18.54 billion, a PE ratio of 24.17, a PEG ratio of 3.03 and a beta of 0.98. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. Hologic, Inc. has a 12 month low of $66.93 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 20.11%. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same period in the prior year, the firm posted $0.89 EPS. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. As a group, equities research analysts forecast that Hologic, Inc. will post 4.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on HOLX. Royal Bank of Canada lifted their price target on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday. UBS Group lifted their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price target on shares of Hologic in a research note on Tuesday, October 15th. Stephens reaffirmed an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Finally, Evercore ISI boosted their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $89.25.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.